Which peptides are studied for hormone conditions?

Short answer

25 profiles here are grouped under “Hormones”: 16 FDA-approved and 9 not FDA-approved.

Each entry below quotes its profile and links to the full answer there.

FDA-approved 16

Not FDA-approved 9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    MIACALCIN (calcitonin salmon) injection, solution · SPL version 9 · published 2026-06-19 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: MIACALCIN (calcitonin salmon), NDA 017808 · original approval July 3, 1986 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    DDAVP (desmopressin acetate) tablet · SPL version 7 · published 2025-12-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  6. 6
    Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  7. 7
    PARSABIV (etelcalcetide) injection, solution · SPL version 15 · published 2026-03-16 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  8. 8
    Drugs@FDA: PARSABIV (etelcalcetide), NDA 208325 · original approval February 7, 2017 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  9. 9
    Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  10. 10
    Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  12. 12
    Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  13. 13
    ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  14. 14
    Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  15. 15
    SUPPRELIN LA (histrelin acetate) implant · SPL version 38 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  16. 16
    Drugs@FDA: SUPPRELIN LA (histrelin acetate), NDA 022058 · original approval May 3, 2007 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  17. 17
    Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  18. 18
    Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  19. 19
    Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  20. 20
    Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  21. 21
    Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  22. 22
    INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  23. 23
    SYNAREL (nafarelin acetate) nasal solution · SPL version 23 · published 2026-03-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  24. 24
    Drugs@FDA: SYNAREL (nafarelin acetate), NDA 019886 · original approval February 13, 1990 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  25. 25
    Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  26. 26
    Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  27. 27
    Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  28. 28
    Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  29. 29
    Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  30. 30
    PITOCIN (oxytocin) injection · SPL version 15 · published 2026-05-21 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  31. 31
    Drugs@FDA: PITOCIN (oxytocin), NDA 018261 · original approval November 19, 1980 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  32. 32
    YORVIPATH (palopegteriparatide) injection, solution · SPL version 10 · published 2026-11-09 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  33. 33
    Drugs@FDA: YORVIPATH (palopegteriparatide), NDA 216490 · original approval August 9, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  34. 34
    SIGNIFOR (pasireotide) injection · SPL version 20 · published 2026-02-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  35. 35
    Drugs@FDA: SIGNIFOR (pasireotide diaspartate), NDA 200677 · original approval December 14, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  36. 36
    TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  37. 37
    Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  38. 38
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  39. 39
    FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  40. 40
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  41. 41
    Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  42. 42
    Examorelin (hexarelin) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  43. 43
    Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  44. 44
    FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  45. 45
    FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  46. 46
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  47. 47
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  48. 48
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026